1. Alfthan O, Jauhiainen K, Kangas L, Käpylä H (1986) Superficial urinary bladder cancinoma: Chemotherapy, retinoids and prevention of relapses. Int J Immunother II: 5–15
2. Böhle A, Nowe CH, Ulmer AJ, Musehold J, Gerdes J, Hofsstetter AG, Flad HD (1990) Elevations of the cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 144: 59–64
3. Böhle A, Thanhöuser A, Ulmer AJ, Ernst M, Flad HD, Jocham D (1993) Dissecting the immunological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomen. J Urol 150: 1932–1939
4. Carbin B-E (1990) Prognostic factors in urinary bladder cancer. Thesis Kongelige Carolinska Medico Chirurgiska Instituter, Stockholm
5. DeBruyne FMJ, Meijden ADPM van der, Geboers ADH, Franssen MPH, Leeuwen MJW van, Steeremberg PA, deJong WM, Ruitenberg JJ (1988) BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. Urology 31: 20–25.